Electronic Supplementary Material

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with *EGFR*+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

Running title: Afatinib in EGFR TKI-Naïve NSCLC: Final Analysis

Haiyan Tu1,a · Jifeng Feng2,b · Meiqi Shi2 · Jun Zhao3 · Yuyan Wang3 · Jianhua Chang4 · Jialei Wang4 · Ying Cheng5 · Jing Zhu5 · Eng-Huat Tan6 · Kai Li7 · Yiping Zhang6 · Victor Lee9 · Cheng-Ta Yang10 · Wu-Chou Su11 · David Chi-Leung Lam12 · BJ Srinivasa13 · Senthil Rajappa14 · Ching-Liang Ho15 · Kwok Chi Lam16 · Yi Hu17 · Shailesh Arjun Bondarde18 · Xiaoqing Liu19 · Yahui Tian20 · Zhiyi Xue20 · Agnieszka Cseh21 · Dennis Chin-Lun Huang22 · Caicun Zhou23 · Yi-Long Wu1

1 Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, 510080, China
2 Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210029, China
3 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department 1 of Thoracic Oncology Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China
4 Fudan University Shanghai Cancer Center, Shanghai, 200032, China
5 Division of Thoracic Oncology, Jilin Province Cancer Hospital, Changchun, 130012, China
6 Department of Medical Oncology, National Cancer Centre, Singapore, 169610, Singapore
7 Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China
8 Zhejiang Cancer Hospital, Hangzhou, 310022, China
9. Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053, China

10. Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan

11. National Cheng Kung University Hospital, Tainan, 704, Taiwan

12. Department of Clinical Oncology, department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong

13. HCG Hospital, Bangalore, 560020, India

14. Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, 500034, India

15. Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, 114, Taiwan

16. Prince of Wales Hospital, Shatin, New Territories, Hong Kong

17. Department of Oncology, Chinese PLA General Hospital, Beijing, 100853, China

18. Shatabdi Superspeciality Hospital, Nashik, 422005, India

19. 307th Hospital of PLA, Beijing, 100070, China

20. Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China

21. Boehringer Ingelheim International GmbH, Ingelheim 55216, Germany

22. Boehringer Ingelheim Taiwan Limited, Taipei, 104, Taiwan

23. Shanghai Pulmonary Hospital, Tongji University, Shanghai, 200433, China

*Both authors contributed equally to the manuscript

**Corresponding author:** Yi-Long Wu, syylwu@live.cn
Electronic Supplementary Material – Fig. S1. (a) TTSP and (b) PFS in patients enrolled in China with and without afatinib dose reduction in the first 6 months of treatment; and (c) TTSP and (d) PFS in patients enrolled in China with and without brain metastases. Abbreviations: PFS, progression-free survival; TTSP, time to symptomatic progression.